Influvac®与Influvac® Tetra的增强被动安全监测:连续七个季节的结果
在德国连续七个季节对Influvac®(2014/15起)和Influvac® Tetra(2018/19起)开展增强被动安全监测,目标每季至少1000名接种者并按五个预设年龄组各100名。反应原性数据与已知安全性特征一致,儿童中Influvac® Tetra接种人数少但未提示不同反应原性特征,未发现安全信号。
要点
- 七季监测中主要目标至少1000名接种者及成人老年人每组100名附加目标均达成。
- 反应原性数据与Influvac®和Influvac® Tetra已知安全性特征一致。
- 儿童中Influvac® Tetra数据基于低接种人数,未提示与Influvac®不同的反应原性特征。
核心结论
- 为Influvac®和Influvac® Tetra建立的增强被动安全监测被证明是符合欧洲药品管理局(EMA)季节性流感疫苗增强安全监测指南目标的稳健有效方法。
- 连续七个季节的安全性数据确认了两种疫苗的良好安全性特征。
研究设计与样本
- 连续七个季节在德国开展增强被动安全监测(EPSS),目标至少1000名接种者,附加目标为五个预设年龄组每组100名接种者。
- 通过应答卡收集预设局部和全身感兴趣不良事件(AEI)的报告率、严重程度和持续时间,接种者填写后于接种后七天通过普通邮件寄回。
- 应答卡还包含呼叫中心号码以加强非预设不良事件的报告。
主要发现
- 所有季节均超过至少1000名接种者的主要目标,也超过100名成人和老年人的附加目标。
- 反应原性数据与Influvac®和Influvac® Tetra的已知安全性特征一致。
- 儿童中,Influvac®监测季节大多达到目标,而Influvac® Tetra监测季节未达到。
- Influvac® Tetra的儿童数据基于低数量接种者,但未提示与Influvac®不同的反应原性特征。
- 未发现安全信号。
局限性
- 原文指出Influvac® Tetra的儿童数据基于低数量接种者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In 2014, the European Medicines Agency (EMA) set out requirements for an enhanced safety surveillance for seasonal influenza vaccines. This paper presents data from the yearly Enhanced Passive Safety Surveillance (EPSS) implemented for Influvac® since season 2014/15 and continued for Influvac® Tetra from season 2018/19 onwards. METHODS: In seven consecutive seasons, an EPSS, aiming for at least 1,000 vaccinees (additional target of 100 vaccinees per five predefined age groups), was conducted in Germany, where market characteristics were expected to allow for a quick generation of representative data. Reactogenicity data in terms of reporting rates, severity and duration of pre-specified local and systemic adverse events of interest (AEI) were collected using response cards, which were completed by vaccinees and returned seven days after vaccination via regular mail. In addition, response cards contained a call center number to enhance reporting of other than pre-specified adverse events. RESULTS: The primary target of at least 1,000 vaccinees was surpassed in all seasons, as was the additional target of 100 adults and elderly. Reactogenicity data were in line with known safety profile of Influvac® and Influvac® Tetra. In children, the target was mostly met in seasons when the EPSS was conducted for Influvac®, but not in seasons when it was conducted for Influvac® Tetra. Although the data for Influvac® Tetra are based on a low number of paediatric vaccinees, they do not indicate a different reactogenicity profile of Influvac® Tetra compared with Influvac®. No signals were identified. CONCLUSION: The EPSS set up for Influvac® and Influvac® Tetra proved a robust and effective methodology to comply with the objectives of EMÁ's guidance on enhanced safety surveillance of seasonal influenza vaccines. Safety data from seven consecutive seasons confirmed the favourable safety profile of both vaccines.
引用
- Moeller-Arendt M, van de Witte S, Nauta J, et al. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons. Vaccine. 2022. PMID: 36517322. doi:10.1016/j.vaccine.2022.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。